Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:7:1-12.
doi: 10.4137/CMO.S7256. Epub 2012 Dec 20.

Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer

Fabien Calcagno  1 , Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, François Kleinclauss, Xavier Pivot, Antoine Thiery-Vuillemin
Affiliations

Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer

Fabien Calcagno et al. Clin Med Insights Oncol. 2013.

Abstract

Prostate cancer (PC) is one of the most common cancers and is a leading cause of death. Its initial growth is dependent on androgens; most patients show an initial response to hormonal therapy but will experience disease progression when PC becomes resistant to castration. In 2004, two key randomized controlled trials demonstrated a benefit for docetaxel-based regimens in the treatment of men with castration-resistant prostate cancer (CRPC). Cabazitaxel (XRP6258, TXD258, and RPR116258A), a tubulin-binding taxane drug as potent as docetaxel in cell lines, was the first treatment able to prolong survival for metastatic CRPC in the post-docetaxel setting. This review describes pharmacologic parameters of this agent followed by a review of clinical trials involving cabazitaxel. Other available treatments and the place of cabazitaxel in metastatic CRPC setting are discussed.

Keywords: cabazitaxel; castrate resistant; chemotherapy; prostate cancer; taxane.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of the probability of overall survival (OS) and progression free survival (PFS) in the phase 3 TROPIC trial. Figure adapted from ref (de Bono et al). Abbreviation: HR, hazard ratio.
Figure 2
Figure 2
Drugs having shown a benefit according to their primary objective in phase 3 trials in patients with CRPC. Abiraterone in predocetaxel setting had 2 primaries and has demonstrated a significant radiological progression free survival benefit and a strong trend in overall survival benefit. Drugs in italic = phase 3 on-going. Abbreviations: CRPC, castration resistant prostate cancer; CSPC, castration sensitive prostate cancer.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, XUJ, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(2):277–300. - PubMed
    1. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000–4, and an overview of trends since 1975. Ann Oncol. 2010;21(6):1323–60. - PubMed
    1. Huggins C, Hodges CV. Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7. - PubMed
    1. Shelley M, Harrison C, Coles B, Stafforth J, Wilt T, Mason M. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database of Syst Rev. 2006;18(4):CD005247. - PubMed
    1. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 2010;70:983–1000. - PubMed

LinkOut - more resources